{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T09:32:16Z","timestamp":1793266336256,"version":"4.5.0"},"reference-count":239,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020453","name":"West Anhui University","doi-asserted-by":"publisher","award":["WGKQ2026032"],"award-info":[{"award-number":["WGKQ2026032"]}],"id":[{"id":"10.13039\/501100020453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.phrs.2026.108471","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:56:13Z","timestamp":1789721773000},"page":"108471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Nanomedicine-based targeted strategies for metabolic dysfunction-associated steatotic liver disease: Unraveling pathogenic crosstalk and overcoming clinical barriers"],"prefix":"10.1016","volume":"233","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8796-0597","authenticated-orcid":false,"given":"Mingyue","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhai","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enhui","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bangxing","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.phrs.2026.108471_bib1","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.phrs.2026.108471_bib2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41575-019-0144-8","article-title":"Past, present and future perspectives in nonalcoholic fatty liver disease","volume":"16","author":"Sanyal","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108471_bib3","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/hep.31173","article-title":"Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: the Growing Impact of NAFLD","volume":"72","author":"Paik","year":"2020","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41572-025-00599-1","article-title":"Metabolic dysfunction-associated steatotic liver disease in adults","volume":"11","author":"Huang","year":"2025","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"4","key":"10.1016\/j.phrs.2026.108471_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201801585","article-title":"Insights into the epidemiology, pathogenesis, and therapeutics of nonalcoholic fatty liver diseases","volume":"6","author":"Yu","year":"2019","journal-title":"Adv. Sci."},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.nano.2006.11.008","article-title":"The present and future of nanotechnology in human health care","volume":"3","author":"Sahoo","year":"2007","journal-title":"Nanomedicine"},{"issue":"2","key":"10.1016\/j.phrs.2026.108471_bib7","article-title":"Advances in nanotechnology for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease","volume":"20","author":"Li","year":"2025","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.phrs.2026.108471_bib8","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.cis.2015.04.006","article-title":"Nanocarriers for the delivery of active ingredients and fractions extracted from natural products used in traditional Chinese medicine (TCM)","volume":"221","author":"Liu","year":"2015","journal-title":"Adv. Colloid Interface Sci."},{"issue":"8","key":"10.1016\/j.phrs.2026.108471_bib9","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.3109\/10717544.2015.1116025","article-title":"Advance of the application of nano-controlled release system in ophthalmic drug delivery","volume":"23","author":"Wang","year":"2016","journal-title":"Drug. Deliv."},{"key":"10.1016\/j.phrs.2026.108471_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114522","article-title":"Stimuli-responsive nanomedicines for hepatic diseases: mechanism, design, recent advances, and clinical translation","volume":"390","author":"Wang","year":"2026","journal-title":"J. Control. Release"},{"issue":"null","key":"10.1016\/j.phrs.2026.108471_bib11","first-page":"4715","article-title":"Nano-Enhanced Diets: Advancing Metabolic Dysfunction-Related Steatotic Liver Disease (MASLD) - A Review, Diabetes, Metabolic Syndrome and Obesity","volume":"18","author":"Herdiana","year":"2025","journal-title":"Targets Ther."},{"issue":"8","key":"10.1016\/j.phrs.2026.108471_bib12","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.phrs.2026.108471_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1433857","article-title":"Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases","volume":"12","author":"Sandireddy","year":"2024","journal-title":"Front. Cell. Dev. Biol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108471_bib14","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3350\/cmh.2024.0268","article-title":"TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD","volume":"30","author":"Sun","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"issue":"18","key":"10.1016\/j.phrs.2026.108471_bib15","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2318619121","article-title":"The fatty liver disease-causing protein PNPLA3-I148M alters lipid droplet-Golgi dynamics","volume":"121","author":"Sherman","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.phrs.2026.108471_bib16","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/gutjnl-2024-333154","article-title":"Hepatic TM6SF2 activates antitumour immunity to suppress metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma and boosts immunotherapy","volume":"74","author":"Zhang","year":"2025","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.phrs.2026.108471_bib17","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.cmet.2025.12.004","article-title":"Human MASLD is a diurnal disease driven by multisystem insulin resistance and reduced insulin availability at night","volume":"38","author":"Marjot","year":"2026","journal-title":"Cell. Metab."},{"issue":"10","key":"10.1016\/j.phrs.2026.108471_bib18","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/j.immuni.2024.08.016","article-title":"Notch signaling regulates macrophage-mediated inflammation in metabolic dysfunction-associated steatotic liver disease","volume":"57","author":"Guo","year":"2024","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.phrs.2026.108471_bib19","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cmet.2024.05.003","article-title":"Metabolic reprogramming in liver fibrosis","volume":"36","author":"Horn","year":"2024","journal-title":"Cell. Metab."},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib20","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1038\/s41467-025-58722-5","article-title":"GPAT4 sustains endoplasmic reticulum homeostasis in endocardial cells and safeguards heart development","volume":"16","author":"Zhao","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2026.108471_bib21","article-title":"Nano-formulations in therapeutic strategies targeting cancer ferroptosis","author":"Zhou","year":"2026","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.phrs.2026.108471_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102691","article-title":"STING mediates hepatocyte pyroptosis in liver fibrosis by Epigenetically activating the NLRP3 inflammasome","volume":"62","author":"Xiao","year":"2023","journal-title":"Redox Biol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108471_bib23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nrm.2016.149","article-title":"Necroptosis in development, inflammation and disease","volume":"18","author":"Weinlich","year":"2017","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108471_bib24","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/15548627.2025.2601035","article-title":"ATG9A-PLA2G6 axis reprograms phospholipid metabolism to drive metabolic liver disease and hepatocellular carcinoma","volume":"22","author":"Zhu","year":"2026","journal-title":"Autophagy"},{"issue":"9","key":"10.1016\/j.phrs.2026.108471_bib25","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41575-025-01089-1","article-title":"Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma","volume":"22","author":"Lau","year":"2025","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.phrs.2026.108471_bib26","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/hep.32235","article-title":"A GLP-1\/GLP-2 receptor dual agonist to treat NASH: Targeting the gut-liver axis and microbiome","volume":"75","author":"Kim","year":"2022","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.phrs.2026.108471_bib27","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/gutjnl-2024-332602","article-title":"Multiomics of the intestine-liver-adipose axis in multiple studies unveils a consistent link of the gut microbiota and the antiviral response with systemic glucose metabolism","volume":"74","author":"Castells-Nobau","year":"2025","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.phrs.2026.108471_bib28","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2025.02.033","article-title":"Integrative metabolism in MASLD and MASH: Pathophysiology and emerging mechanisms","volume":"83","author":"Steinberg","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2026.108471_bib29","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1146\/annurev-pathmechdis-031521-030435","article-title":"Recent Advances in Understanding of Pathogenesis of Alcohol-Associated Liver Disease","volume":"18","author":"Wu","year":"2023","journal-title":"Annu. Rev. Pathol."},{"issue":"6","key":"10.1016\/j.phrs.2026.108471_bib30","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.7150\/thno.91572","article-title":"Hepatic progenitor cell-originated ductular reaction facilitates liver fibrosis through activation of hedgehog signaling","volume":"14","author":"Hu","year":"2024","journal-title":"Theranostics"},{"issue":"7","key":"10.1016\/j.phrs.2026.108471_bib31","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/s41422-025-01110-x","article-title":"Lysosomal EGFR acts as a Rheb-GEF independent of its kinase activity to activate mTORC1","volume":"35","author":"He","year":"2025","journal-title":"Cell. Res."},{"issue":"6","key":"10.1016\/j.phrs.2026.108471_bib32","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1002\/hep.32064","article-title":"Fructose-1,6-Bisphosphate Aldolase B Depletion Promotes Hepatocellular Carcinogenesis Through Activating Insulin Receptor Signaling and Lipogenesis","volume":"74","author":"Liu","year":"2021","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.phrs.2026.108471_bib33","article-title":"Progressive fibrosis in human MASLD is associated with spatially linked transcriptomic signatures of metabolic reprogramming and senescence","volume":"8","author":"Vu","year":"2026","journal-title":"JHEP Rep."},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib34","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12944-026-02867-9","article-title":"Dysregulation of the AMPK-SREBP1-FASN axis in MASLD: driving a vicious cycle of lipotoxicity and metabolic-immune crosstalk","volume":"25","author":"Zhao","year":"2026","journal-title":"Lipids Health Dis."},{"issue":"12","key":"10.1016\/j.phrs.2026.108471_bib35","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1038\/s41588-025-02407-8","article-title":"Spatially resolved multi-omics of human metabolic dysfunction-associated steatotic liver disease","volume":"57","author":"Li","year":"2025","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib36","doi-asserted-by":"crossref","first-page":"109","DOI":"10.15403\/jgld-6581","article-title":"The Influence of Epigenetic Mechanisms on the Development of Metabolic Dysfunction Associated Steatotic Liver Disease: A Review","volume":"35","author":"Zhelezniakova","year":"2026","journal-title":"J. Gastrointest. liver Dis. JGLD"},{"key":"10.1016\/j.phrs.2026.108471_bib37","article-title":"Loss of immunometabolic adaptability in MASH: gut-derived signals drive macrophage reprogramming and fibrosis","volume":"17","author":"Li","year":"2026","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib38","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41746-026-02352-8","article-title":"Integrating multi-omics and machine learning systematically deciphers cellular heterogeneity and fibrotic regulatory networks in the progression from MASLD to MASH","volume":"9","author":"Wen","year":"2026","journal-title":"npj Digit. Med."},{"key":"10.1016\/j.phrs.2026.108471_bib39","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.3350\/cmh.2024.0438","article-title":"Precision medicine and nucleotide-based therapeutics to treat steatotic liver disease","author":"Caddeo","year":"2025","journal-title":"Clin. Mol. Hepatol. 31(Suppl. )"},{"issue":"833","key":"10.1016\/j.phrs.2026.108471_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adx0368","article-title":"Anti-FAP CAR T cells produced in vivo reduce fibrosis and restore liver homeostasis in metabolic dysfunction-associated steatohepatitis","volume":"18","author":"Yashaswini","year":"2026","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.phrs.2026.108471_bib41","first-page":"496","article-title":"A charge reversal nano-assembly prevents hepatic steatosis by resolving inflammation and improving lipid metabolism","volume":"45","author":"Wang","year":"2025","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.phrs.2026.108471_bib42","article-title":"Beyond GLP-1: The promise of polyagonists in MASLD and MASH\u2014A systematic review of randomized trials","author":"Slaton","year":"2026","journal-title":"JAPhA Pharmacother."},{"issue":"2","key":"10.1016\/j.phrs.2026.108471_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25021109","article-title":"The Role of SCAP\/SREBP as Central Regulators of Lipid Metabolism in Hepatic Steatosis","volume":"25","author":"Chandrasekaran","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108471_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177890","article-title":"Effectiveness and safety of the SREBP1\/2 inhibitor, fatostatin, in a preclinical model of metabolic dysfunction-associated steatotic liver disease progression","volume":"1003","author":"Arora","year":"2025","journal-title":"Eur. J. Pharmacol."},{"issue":"30","key":"10.1016\/j.phrs.2026.108471_bib45","doi-asserted-by":"crossref","first-page":"34328","DOI":"10.1021\/acsami.2c05889","article-title":"Redox-Unlockable Nanoparticle-Based MST1 Delivery System to Attenuate Hepatic Steatosis via the AMPK\/SREBP-1c Signaling Axis","volume":"14","author":"Li","year":"2022","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.phrs.2026.108471_bib46","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.2147\/IJN.S510577","article-title":"Liver-Targeting Nanoparticles GA-MSe@AR Treat NAFLD Through Dual Lipid-Lowering and Antioxidant Efficacy","volume":"20","author":"Lei","year":"2025","journal-title":"Int. J. Nanomed."},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib47","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cmet.2025.11.015","article-title":"Dual inhibition of ACLY and ACSS2 by EVT0185 reduces steatosis, hepatic stellate cell activation, and fibrosis in mouse models of MASH","volume":"38","author":"Di Pastena","year":"2026","journal-title":"Cell. Metab."},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib48","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12951-025-03228-x","article-title":"Naringenin cationic lipid-modified nanoparticles mitigate MASLD progression by modulating lipid homeostasis and gut microbiota","volume":"23","author":"Dong","year":"2025","journal-title":"J. Nanobiotechnology"},{"issue":"12","key":"10.1016\/j.phrs.2026.108471_bib49","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S2468-1253(24)00246-2","article-title":"Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Loomba","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"10505","key":"10.1016\/j.phrs.2026.108471_bib50","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(25)00979-1","article-title":"Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"406","author":"Loomba","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib51","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1038\/s41467-025-58790-7","article-title":"Hepatic AKAP1 deficiency exacerbates diet-induced MASLD by enhancing GPAT1-mediated lysophosphatidic acid synthesis","volume":"16","author":"He","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib52","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41467-023-44416-3","article-title":"A nanoemulsion targeting adipose hypertrophy and hyperplasia shows anti-obesity efficiency in female mice","volume":"15","author":"Lu","year":"2024","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.phrs.2026.108471_bib53","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jhep.2024.12.045","article-title":"Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD","volume":"82","author":"Barb","year":"2025","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108471_bib54","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1097\/HEP.0000000000001475","article-title":"Chiglitazar in MASLD with hypertriglyceridemia and insulin resistance: A phase II, randomized, double-blind, placebo-controlled study","volume":"83","author":"Sun","year":"2026","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.phrs.2026.108471_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/cells9071638","article-title":"Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease","volume":"9","author":"Fougerat","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib56","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1021\/acs.molpharmaceut.2c00549","article-title":"Engineered Fenofibrate as Oxidation-Sensitive Nanoparticles with ROS Scavenging and PPAR\u03b1-Activating Bioactivity to Ameliorate Nonalcoholic Fatty Liver Disease","volume":"20","author":"Du","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.phrs.2026.108471_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.foodchem.2022.132954","article-title":"A designed self-microemulsion delivery system for dihydromyricetin and its dietary intervention effect on high-fat-diet fed mice","volume":"390","author":"Lyu","year":"2022","journal-title":"Food Chem."},{"key":"10.1016\/j.phrs.2026.108471_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2019.110528","article-title":"Fe(3)O(4)@OA@Poloxamer nanoparticles lower triglyceride in hepatocytes through liposuction effect and nano-enzyme effect","volume":"184","author":"Sun","year":"2019","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib59","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11901-025-00708-4","article-title":"Resmetirom in the Management of MASLD: What Clinicians Need to Know","volume":"24","author":"Xu","year":"2025","journal-title":"Curr. Hepatol. Rep."},{"key":"10.1016\/j.phrs.2026.108471_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118249","article-title":"Therapeutic implications of obeticholic acid, a farnesoid X receptor agonist, in the treatment of liver fibrosis","volume":"189","author":"Azizsoltani","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.phrs.2026.108471_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156128","article-title":"PPAR\u03b1-ERR\u03b1 crosstalk mitigates metabolic dysfunction-associated steatotic liver disease progression","volume":"164","author":"Antwi","year":"2025","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib62","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s44324-024-00013-6","article-title":"Unlocking therapeutic potential: exploring cross-talk among emerging nuclear receptors to combat metabolic dysfunction in steatotic liver disease","volume":"2","author":"Antwi","year":"2024","journal-title":"NPJ Metab. Health Dis."},{"key":"10.1016\/j.phrs.2026.108471_bib63","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jconrel.2019.06.023","article-title":"The hepatic-targeted, resveratrol loaded nanoparticles for relief of high fat diet-induced nonalcoholic fatty liver disease","volume":"307","author":"Teng","year":"2019","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib64","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1021\/acs.biomac.1c01360","article-title":"Construction of Glycogen-Based Nanoparticles Loaded with Resveratrol for the Alleviation of High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease","volume":"23","author":"Li","year":"2022","journal-title":"Biomacromolecules"},{"issue":"11","key":"10.1016\/j.phrs.2026.108471_bib65","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.2337\/db14-0263","article-title":"SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis","volume":"63","author":"Xu","year":"2014","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.phrs.2026.108471_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/cells9112367","article-title":"The Role of PPARs in Disease","volume":"9","author":"Wagner","year":"2020","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.phrs.2026.108471_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/cells9081882","article-title":"Sirt1-PPARS Cross-Talk in Complex Metabolic Diseases and Inherited Disorders of the One Carbon Metabolism","volume":"9","author":"Kosgei","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib68","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jhep.2012.08.008","article-title":"miR-34a\/SIRT1\/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease","volume":"58","author":"Castro","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2026.108471_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnutbio.2025.110138","article-title":"CYP4A14-PPAR\u03b1 axis serves as a therapeutic target for ursodeoxycholic acid in ameliorating high-fat diet-induced MASLD","volume":"147","author":"Li","year":"2026","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.phrs.2026.108471_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2022.119388","article-title":"Responsive oligochitosan nano-vesicles with ursodeoxycholic acid and exenatide for NAFLD synergistic therapy via SIRT1","volume":"288","author":"Xie","year":"2022","journal-title":"Carbohydr. Polym."},{"issue":"7","key":"10.1016\/j.phrs.2026.108471_bib71","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41389-020-00251-5","article-title":"Suppressing DRP1-mediated mitochondrial fission and mitophagy increases mitochondrial apoptosis of hepatocellular carcinoma cells in the setting of hypoxia","volume":"9","author":"Lin","year":"2020","journal-title":"Oncogenesis"},{"key":"10.1016\/j.phrs.2026.108471_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.jphotobiol.2025.113209","article-title":"Photobiomodulation mediates endoplasmic reticulum-mitochondria contact and ameliorates lipotoxicity in MASLD via Mfn2 upregulation","volume":"270","author":"Jiang","year":"2025","journal-title":"J. Photochem. Photobiol. B"},{"key":"10.1016\/j.phrs.2026.108471_bib73","doi-asserted-by":"crossref","DOI":"10.3923\/tmr.2024.112.123","article-title":"Mitophagy in the Pathogenesis of Obesity-Associated Cardiovascular Diseases: New Mechanistic and Therapeutic Insights","author":"Huang","year":"2024","journal-title":"Trends Med. Res."},{"key":"10.1016\/j.phrs.2026.108471_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2025.171980","article-title":"TFEB-driven autophagy enhancement via a ROS-triggered NIR-II nanoplatform for targeted non-alcoholic fatty liver disease therapy","volume":"528","author":"Wu","year":"2026","journal-title":"Chem. Eng. J."},{"issue":"21","key":"10.1016\/j.phrs.2026.108471_bib75","doi-asserted-by":"crossref","first-page":"7076","DOI":"10.1039\/D1BM00689D","article-title":"Poly-ion complex micelles effectively deliver CoA-conjugated CPT1A inhibitors to modulate lipid metabolism in brain cells","volume":"9","author":"Paraiso","year":"2021","journal-title":"Biomater. Sci."},{"issue":"10","key":"10.1016\/j.phrs.2026.108471_bib76","article-title":"Antioxidative Self-Assembling Nanoparticles Attenuate the Development of Steatohepatitis and Inhibit Hepatocarcinogenesis in Mice","volume":"11","author":"Watahiki","year":"2022","journal-title":"Antioxid. (Basel)"},{"issue":"6","key":"10.1016\/j.phrs.2026.108471_bib77","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.clinre.2019.03.008","article-title":"Hydrogen-rich water reduces liver fat accumulation and improves liver enzyme profiles in patients with non-alcoholic fatty liver disease: a randomized controlled pilot trial","volume":"43","author":"Korovljev","year":"2019","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"7","key":"10.1016\/j.phrs.2026.108471_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12071444","article-title":"Hydrogen-Rich Water (HRW) Reduces Fatty Acid-Induced Lipid Accumulation and Oxidative Stress Damage through Activating AMP-Activated Protein Kinase in HepG2 Cells","volume":"12","author":"Tsou","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.phrs.2026.108471_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121030","article-title":"Nanocapsule-mediated sustained H(2) release in the gut ameliorates metabolic dysfunction-associated fatty liver disease","volume":"276","author":"Jin","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.phrs.2026.108471_bib80","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.actbio.2023.09.030","article-title":"Stimuli-responsive pressure-strain sensor-based conductive hydrogel for alleviated non-alcoholic fatty liver disease by scavenging reactive oxygen species in adipose tissue","volume":"171","author":"Shit","year":"2023","journal-title":"Acta Biomater."},{"issue":"7","key":"10.1016\/j.phrs.2026.108471_bib81","article-title":"FGF21 Reduces Lipid Accumulation in Bovine Hepatocytes by Enhancing Lipid Oxidation and Reducing Lipogenesis via AMPK Signaling","volume":"12","author":"Kong","year":"2022","journal-title":"Anim. (Basel)"},{"issue":"4","key":"10.1016\/j.phrs.2026.108471_bib82","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.devcel.2018.12.021","article-title":"FGF15 Activates Hippo Signaling to Suppress Bile Acid Metabolism and Liver Tumorigenesis","volume":"48","author":"Ji","year":"2019","journal-title":"Dev. Cell."},{"key":"10.1016\/j.phrs.2026.108471_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123576","article-title":"Oral delivery of chitosan-bilirubin nanoparticles alleviates hepatic inflammation and fibrosis in metabolic dysfunction-associated steatohepatitis","volume":"325","author":"Rahman","year":"2026","journal-title":"Biomaterials"},{"key":"10.1016\/j.phrs.2026.108471_bib84","doi-asserted-by":"crossref","first-page":"5645","DOI":"10.2147\/IJN.S500891","article-title":"The Nb(4)C(3) MXenzyme Attenuates MASH by Scavenging ROS in a Mouse Model","volume":"20","author":"He","year":"2025","journal-title":"Int. J. Nanomed."},{"issue":"8","key":"10.1016\/j.phrs.2026.108471_bib85","article-title":"Combination of hydroxycitric acid and capsaicin regulates IRS-1\/AMPK-mTOR-SREBP-1c Axis\/NLRP3-NF-\u03baB\/Nrf-2-ARE signaling pathways to ameliorate the two-hit process in high-fat diet-induced hepatic steatosis","volume":"1870","author":"Uddandrao","year":"2025","journal-title":"Biochim. Biophys. Acta Mol. Cell. Biol. Lipids"},{"key":"10.1016\/j.phrs.2026.108471_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2025.124737","article-title":"Chitosan and chito-oligosaccharides as multifunctional therapeutics for metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"375","author":"Zhou","year":"2026","journal-title":"Carbohydr. Polym."},{"issue":"45","key":"10.1016\/j.phrs.2026.108471_bib87","article-title":"Genome-Wide Profiling of H3K27ac Identifies TDO2 as a Pivotal Therapeutic Target in Metabolic Associated Steatohepatitis Liver Disease","volume":"11","author":"Zhu","year":"2024","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib88","doi-asserted-by":"crossref","first-page":"9815","DOI":"10.1038\/s41598-025-92282-4","article-title":"Mechanisms of rifaximin inhibition of hepatic fibrosis in mice with metabolic dysfunction associated steatohepatitis through the TLR4\/NF\u03baB pathway","volume":"15","author":"Qiu","year":"2025","journal-title":"Sci. Rep."},{"issue":"Pt 2","key":"10.1016\/j.phrs.2026.108471_bib89","article-title":"Baicalin inhibits Listeria monocytogenes-induced embryonic loss through the JNK\/NEK7-NLRP3\/GSDMD pathway","volume":"168","author":"Zhang","year":"2026","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.phrs.2026.108471_bib90","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1652608","article-title":"Analysis of GSDMD-N abnormality promoting neutrophil NETs mediated RA disease through NLRP3-dependent pathway","volume":"16","author":"Sang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2026.108471_bib91","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2022.01.038","article-title":"Hepatic macrophage targeted siRNA lipid nanoparticles treat non-alcoholic steatohepatitis","volume":"343","author":"Zhou","year":"2022","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.phrs.2026.108471_bib92","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1002\/hep.30093","article-title":"High Mobility Group Box-1 Drives Fibrosis Progression Signaling via the Receptor for Advanced Glycation End Products in Mice","volume":"68","author":"Ge","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.phrs.2026.108471_bib93","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/hep.29544","article-title":"Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis","volume":"67","author":"Krenkel","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.phrs.2026.108471_bib94","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","article-title":"Triggering and resolution of inflammation in NASH","volume":"15","author":"Schuster","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib95","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s44324-025-00083-0","article-title":"Sterile inflammation in MASH: emerging role of extracellular RNA and therapeutic strategies","volume":"3","author":"Raza","year":"2025","journal-title":"NPJ Metab. Health Dis."},{"key":"10.1016\/j.phrs.2026.108471_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177971","article-title":"HBHP ameliorates CCL4-induced liver fibrosis in rats by inhibiting HMGB1-mediated inflammatory response through binding to the HMGB1-A box","volume":"1004","author":"Luo","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108471_bib97","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.freeradbiomed.2026.03.022","article-title":"lncRNA-driven multi-omics reconstitution engineers EVs for macrophage-targeted and anti-inflammatory therapy in MASLD","volume":"249","author":"Liu","year":"2026","journal-title":"Free. Radic. Biol. Med."},{"issue":"5","key":"10.1016\/j.phrs.2026.108471_bib98","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nri.2017.11","article-title":"Liver macrophages in tissue homeostasis and disease","volume":"17","author":"Krenkel","year":"2017","journal-title":"Nat. Rev. Immunol."},{"issue":"10","key":"10.1016\/j.phrs.2026.108471_bib99","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1021\/acs.bioconjchem.5c00282","article-title":"Mannose-Conjugated Cholesterol Containing Lipid Nanoparticles for Active Targeted mRNA Delivery to Liver Sinusoidal Endothelial and Kupffer Cells","volume":"36","author":"Kim","year":"2025","journal-title":"Bioconjug Chem."},{"key":"10.1016\/j.phrs.2026.108471_bib100","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jconrel.2022.04.034","article-title":"Celastrol-loaded lactosylated albumin nanoparticles attenuate hepatic steatosis in non-alcoholic fatty liver disease","volume":"347","author":"Fan","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.phrs.2026.108471_bib101","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jconrel.2021.01.025","article-title":"Nano-designed carbon monoxide donor SMA\/CORM2 exhibits protective effect against acetaminophen induced liver injury through macrophage reprograming and promoting liver regeneration","volume":"331","author":"Song","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.phrs.2026.108471_bib102","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.actbio.2023.08.009","article-title":"Exploring the therapeutic potential of a nano micelle containing a carbon monoxide-releasing molecule for metabolic-associated fatty liver disease by modulating hypoxia-inducible factor-1\u03b1","volume":"169","author":"Cui","year":"2023","journal-title":"Acta Biomater."},{"key":"10.1016\/j.phrs.2026.108471_bib103","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.actbio.2022.03.024","article-title":"Nanoformulation of a carbon monoxide releasing molecule protects against cyclosporin A-induced nephrotoxicity and renal fibrosis via the suppression of the NLRP3 inflammasome mediated TGF-\u03b2\/Smad pathway","volume":"144","author":"Xia","year":"2022","journal-title":"Acta Biomater."},{"issue":"7","key":"10.1016\/j.phrs.2026.108471_bib104","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1021\/jm1011534","article-title":"Synthesis and biological evaluation of novel 5-benzylidenethiazolidine-2,4-dione derivatives for the treatment of inflammatory diseases","volume":"54","author":"Ma","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108471_bib105","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.2147\/IJN.S202821","article-title":"Mixed micelles loaded with the 5-benzylidenethiazolidine-2,4-dione derivative SKLB023 for efficient treatment of non-alcoholic steatohepatitis","volume":"14","author":"Li","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.phrs.2026.108471_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106208","article-title":"Baicalin and its nanoliposomes ameliorates nonalcoholic fatty liver disease via suppression of TLR4 signaling cascade in mice","volume":"80","author":"Liu","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"Pt 3","key":"10.1016\/j.phrs.2026.108471_bib107","article-title":"Enhancing stability of liposomes using high molecular weight chitosan to promote antioxidative stress effects and lipid-lowering activity of encapsulated lutein in vivo and in vitro","volume":"253","author":"Zhang","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108471_bib108","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/am.2013.88","article-title":"Cerium oxide nanoparticle: a remarkably versatile rare earth nanomaterial for biological applications","volume":"6","author":"Xu","year":"2014","journal-title":"NPG Asia Mater."},{"issue":"21","key":"10.1016\/j.phrs.2026.108471_bib109","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242115728","article-title":"Effectiveness of Cerium Oxide Nanoparticles in Non-Alcoholic Fatty Liver Disease Evolution Using In Vivo and In Vitro Studies: A Systematic Review","volume":"24","author":"Sandoval","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.phrs.2026.108471_bib110","doi-asserted-by":"crossref","DOI":"10.3390\/biom9090425","article-title":"Beyond the Scavenging of Reactive Oxygen Species (ROS): Direct Effect of Cerium Oxide Nanoparticles in Reducing Fatty Acids Content in an In Vitro Model of Hepatocellular Steatosis","volume":"9","author":"Parra-Robert","year":"2019","journal-title":"Biomolecules"},{"issue":"6","key":"10.1016\/j.phrs.2026.108471_bib111","doi-asserted-by":"crossref","DOI":"10.1093\/lifemeta\/loae026","article-title":"Phytic acid-based nanomedicine against mTOR represses lipogenesis and immune response for metabolic dysfunction-associated steatohepatitis therapy","volume":"3","author":"Xu","year":"2024","journal-title":"Life Metab."},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib112","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12951-023-02276-5","article-title":"NOS-like activity of CeO(2) nanozymes contributes to diminishing the vascular plaques","volume":"22","author":"Sun","year":"2024","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.phrs.2026.108471_bib113","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.biopha.2017.03.099","article-title":"Cerium dioxide nanoparticles possess anti-inflammatory properties in the conditions of the obesity-associated NAFLD in rats","volume":"90","author":"Kobyliak","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.phrs.2026.108471_bib114","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.freeradbiomed.2025.09.010","article-title":"Neonatal liver-derived FTH1-enriched extracellular vesicles attenuate ferroptosis and ameliorate MASLD pathogenesis","volume":"240","author":"Zeng","year":"2025","journal-title":"Free. Radic. Biol. Med."},{"key":"10.1016\/j.phrs.2026.108471_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115333","article-title":"Amlodipine and perindopril modulate miR-874-3p expression to regulate ferroptosis-linked LPCAT3\/LACS4\/GPX4 Axis and gut dysbiosis in metabolic-associated steatohepatitis","volume":"164","author":"Matboli","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"46","key":"10.1016\/j.phrs.2026.108471_bib116","doi-asserted-by":"crossref","first-page":"54677","DOI":"10.1021\/acsami.1c14674","article-title":"Fluorescent Egg White-Based Carbon Dots as a High-Sensitivity Iron Chelator for the Therapy of Nonalcoholic Fatty Liver Disease by Iron Overload in Zebrafish","volume":"13","author":"Yu","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.phrs.2026.108471_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122230","article-title":"Inhibition of free heme-catalyzed Fenton-like reaction prevents non-alcoholic fatty liver disease by hepatocyte-targeted hydrogen delivery","volume":"301","author":"Zhao","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.phrs.2026.108471_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcis.2025.138872","article-title":"A multifunctional L-arginine-linked melanin Nanozyme for Theranostic applications in liver fibrosis: Non-invasive dual-modal imaging and reactive oxygen species scavenging for Pyroptosis suppression","volume":"702","author":"Li","year":"2026","journal-title":"J. Colloid Interface Sci."},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib119","article-title":"Engineered Akkermansia muciniphila vesicles for targeted pyroptosis and trained immunity to enhance immunotherapy in hepatocellular carcinoma","volume":"7","author":"Huang","year":"2026","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.phrs.2026.108471_bib120","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2025.1718799","article-title":"Restoring metabolic flexibility: targeting organelle interaction networks in the pathogenesis and therapy of MASLD","volume":"13","author":"Liu","year":"2025","journal-title":"Front. Cell. Dev. Biol."},{"issue":"9","key":"10.1016\/j.phrs.2026.108471_bib121","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa2022166","article-title":"A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis","volume":"384","author":"China","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.phrs.2026.108471_bib122","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1002\/hep.31857","article-title":"Functional Characterization of Organoids Derived From Irreversibly Damaged Liver of Patients With NASH","volume":"74","author":"McCarron","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2026.108471_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122291","article-title":"Long-term and liver-selected ginsenoside C-K nanoparticles retard NAFLD progression by restoring lipid homeostasis","volume":"301","author":"Yue","year":"2023","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib124","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.molcel.2020.05.007","article-title":"Acetyl-CoA Derived from Hepatic Peroxisomal \u03b2-Oxidation Inhibits Autophagy and Promotes Steatosis via mTORC1 Activation","volume":"79","author":"He","year":"2020","journal-title":"Mol. Cell."},{"key":"10.1016\/j.phrs.2026.108471_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2025.156416","article-title":"NSD2 exacerbates metabolic dysfunction-associated steatotic liver disease progression by suppressing TFEB-mediated autophagy-lysosomal pathway","volume":"174","author":"Qiao","year":"2026","journal-title":"Metabolism"},{"issue":"5","key":"10.1016\/j.phrs.2026.108471_bib126","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26052253","article-title":"Poria cocos-Derived Exosome-like Nanovesicles Alleviate Metabolic Dysfunction-Associated Fatty Liver Disease by Promoting Mitophagy and Inhibiting NLRP3 Inflammasome Activation","volume":"26","author":"Wang","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.phrs.2026.108471_bib127","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.tibs.2020.12.008","article-title":"Revisiting Extracellular RNA Release, Processing, and Function","volume":"46","author":"Tosar","year":"2021","journal-title":"Trends Biochem. Sci."},{"issue":"4","key":"10.1016\/j.phrs.2026.108471_bib128","doi-asserted-by":"crossref","DOI":"10.1136\/egastro-2024-100115","article-title":"Mechanistic role of long non-coding RNAs in the pathogenesis of metabolic dysfunction-associated steatotic liver disease and fibrosis","volume":"2","author":"Wade","year":"2024","journal-title":"eGastroenterology"},{"key":"10.1016\/j.phrs.2026.108471_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156114","article-title":"A3AR antagonism mitigates metabolic dysfunction-associated steatotic liver disease by exploiting monocyte-derived Kupffer cell necroptosis and inflammation resolution","volume":"164","author":"Park","year":"2025","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.phrs.2026.108471_bib130","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1097\/HEP.0000000000001098","article-title":"TREM2 macrophages mediate the beneficial effects of bariatric surgery against MASH","volume":"81","author":"Fredrickson","year":"2025","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.phrs.2026.108471_bib131","article-title":"Synthetic cleavage-resistant TREM2 boosts macrophage efferocytosis to treat inflammatory diseases","volume":"7","author":"Dong","year":"2026","journal-title":"Cell. Rep. Med."},{"issue":"10","key":"10.1016\/j.phrs.2026.108471_bib132","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1021\/acs.nanolett.2c04726","article-title":"The Combination of Sinusoidal Perfusion Enhancement and Apoptosis Inhibition by Riociguat Plus a Galactose-PEGylated Bilirubin Multiplexing Nanomedicine Ameliorates Liver Fibrosis Progression","volume":"23","author":"Li","year":"2023","journal-title":"Nano Lett."},{"issue":"3","key":"10.1016\/j.phrs.2026.108471_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.108285","article-title":"Amyloid precursor protein promotes MASH progression by upregulating death receptor 6-mediated hepatocyte apoptosis","volume":"301","author":"Guo","year":"2025","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.phrs.2026.108471_bib134","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1038\/s42255-025-01355-1","article-title":"A non-apoptotic caspase-8-meteorin pathway in hepatocytes promotes MASH fibrosis","volume":"7","author":"Wang","year":"2025","journal-title":"Nat. Metab."},{"issue":"2","key":"10.1016\/j.phrs.2026.108471_bib135","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2796.2005.01528.x","article-title":"Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review","volume":"258","author":"Carlson","year":"2005","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.phrs.2026.108471_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120576","article-title":"Inositol hexanicotinate self-micelle solid dispersion is an efficient drug delivery system in the mouse model of non-alcoholic fatty liver disease","volume":"602","author":"Zheng","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"15","key":"10.1016\/j.phrs.2026.108471_bib137","article-title":"Engineering Cell Membrane-Based Nanotherapeutics to Target Inflammation","volume":"6","author":"Yan","year":"2019","journal-title":"Adv. Sci. (Weinh. )"},{"key":"10.1016\/j.phrs.2026.108471_bib138","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jconrel.2015.02.022","article-title":"Asialoglycoprotein receptor mediated hepatocyte targeting - strategies and applications","volume":"203","author":"D'Souza","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.phrs.2026.108471_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114236","article-title":"Regulatory guidelines and preclinical tools to study the biodistribution of RNA therapeutics","volume":"184","author":"Vervaeke","year":"2022","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.phrs.2026.108471_bib140","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.actbio.2023.10.038","article-title":"Engineering a biomimetic system for hepatocyte-specific RNAi treatment of non-alcoholic fatty liver disease","volume":"174","author":"He","year":"2024","journal-title":"Acta Biomater."},{"key":"10.1016\/j.phrs.2026.108471_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122585","article-title":"Fat fighting liraglutide based nano-formulation to reverse obesity: Design, development and animal trials","volume":"634","author":"Jakhar","year":"2023","journal-title":"Int. J. Pharm."},{"issue":"11","key":"10.1016\/j.phrs.2026.108471_bib142","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.cmet.2025.09.011","article-title":"The enedioic acid analog 326E alleviates metabolic dysfunction-associated steatohepatitis via dual targeting at ACLY and PPAR\u03b1","volume":"37","author":"Xie","year":"2025","journal-title":"Cell. Metab."},{"issue":"11","key":"10.1016\/j.phrs.2026.108471_bib143","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.phrs.2026.108471_bib144","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12060590","article-title":"Targeting Activated Hepatic Stellate Cells Using Collagen-Binding Chitosan Nanoparticles for siRNA Delivery to Fibrotic Livers","volume":"12","author":"Azzam","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.phrs.2026.108471_bib145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mattod.2024.07.005","article-title":"PDGFR-targeted nanovesicles for restraining breast cancer hepatic metastasis via hepatic stellate cell regression and NK cell activation","volume":"79","author":"Kong","year":"2024","journal-title":"Mater. Today"},{"key":"10.1016\/j.phrs.2026.108471_bib146","doi-asserted-by":"crossref","first-page":"9135","DOI":"10.2147\/IJN.S512005","article-title":"Co-Assembled Nanoparticles Comprising Sorafenib and Hederagenin Derivative for Enhanced Anti-Hepatic Fibrosis Activity","volume":"20","author":"Lu","year":"2025","journal-title":"Int. J. Nanomed."},{"issue":"16","key":"10.1016\/j.phrs.2026.108471_bib147","doi-asserted-by":"crossref","first-page":"15444","DOI":"10.1021\/acsnano.4c15562","article-title":"Circularized Supramolecular Spherical Nucleic Acids Alleviates Liver Fibrosis through Blocking Upstream Activation and Reversing Activation State of Hepatic Stellate Cells","volume":"19","author":"Xu","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.phrs.2026.108471_bib148","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jconrel.2019.04.022","article-title":"An integrin-based nanoparticle that targets activated hepatic stellate cells and alleviates liver fibrosis","volume":"303","author":"Li","year":"2019","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib149","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2025.111237","article-title":"A c(RGDyK)-modified ROS-responsive polymeric micelle for hepatic stellate cell targeting","volume":"37","author":"Liu","year":"2026","journal-title":"Chin. Chem. Lett."},{"issue":"4","key":"10.1016\/j.phrs.2026.108471_bib150","doi-asserted-by":"crossref","DOI":"10.3390\/cells14040266","article-title":"Mechanosignaling via Integrins: Pivotal Players in Liver Fibrosis Progression and Therapy","volume":"14","author":"Sharip","year":"2025","journal-title":"Cells"},{"issue":"813","key":"10.1016\/j.phrs.2026.108471_bib151","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ads9470","article-title":"Resolving fibrosis by stimulating HSC-dependent extracellular matrix degradation","volume":"17","author":"Sharma","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.phrs.2026.108471_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2025.102641","article-title":"Sono-mediated glutamine metabolic nanoplatform against liver fibrosis via breaking the vicious self-injury of activated hepatic stellate cells","volume":"61","author":"Yang","year":"2025","journal-title":"Nano Today"},{"issue":"11","key":"10.1016\/j.phrs.2026.108471_bib153","doi-asserted-by":"crossref","first-page":"10113","DOI":"10.1021\/acsnano.2c12831","article-title":"Biological Hyperthermia-Inducing Nanoparticles for Specific Remodeling of the Extracellular Matrix Microenvironment Enhance Pro-Apoptotic Therapy in Fibrosis","volume":"17","author":"Zhang","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.phrs.2026.108471_bib154","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jconrel.2021.03.016","article-title":"Matrix metalloproteinase-1 decorated polymersomes, a surface-active extracellular matrix therapeutic, potentiates collagen degradation and attenuates early liver fibrosis","volume":"332","author":"Geervliet","year":"2021","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib155","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1021\/acsami.4c15494","article-title":"Quercetin-Loaded Melanin Nanoparticles Decorated with Collagenase Mediates Synergistic Immunomodulation and Restores Extracellular Matrix Homeostasis in Liver Fibrosis","volume":"17","author":"Li","year":"2025","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"24","key":"10.1016\/j.phrs.2026.108471_bib156","doi-asserted-by":"crossref","first-page":"6879","DOI":"10.1039\/D5BM01262G","article-title":"Cationic PPC liposomes with dual targeting modules for enhanced liver fibrosis therapy via the extracellular matrix barrier","volume":"13","author":"Li","year":"2025","journal-title":"Biomater. Sci."},{"issue":"5","key":"10.1016\/j.phrs.2026.108471_bib157","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1016\/j.apsb.2024.02.017","article-title":"A combined nanotherapeutic approach targeting farnesoid X receptor, ferroptosis, and fibrosis for nonalcoholic steatohepatitis treatment","volume":"14","author":"Fu","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"31","key":"10.1016\/j.phrs.2026.108471_bib158","article-title":"Smart Microneedle Arrays Integrating Cell-Free Therapy and Nanocatalysis to Treat Liver Fibrosis","volume":"11","author":"Xu","year":"2024","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"4","key":"10.1016\/j.phrs.2026.108471_bib159","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1021\/acs.molpharmaceut.4c01135","article-title":"Suppression of Liver Fibrogenesis with Photothermal Sorafenib Nanovesicles via Selectively Inhibiting Glycolysis and Amplification of Active HSCs","volume":"22","author":"Xiang","year":"2025","journal-title":"Mol. Pharm."},{"issue":"4","key":"10.1016\/j.phrs.2026.108471_bib160","article-title":"Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations","volume":"13","author":"Long","year":"2024","journal-title":"Biol. (Basel)"},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib161","doi-asserted-by":"crossref","DOI":"10.1186\/s12951-026-04421-2","article-title":"Layer-by-layer engineered outer membrane vesicles enable oral upadacitinib delivery for inflammation control and fibrosis attenuation in ulcerative colitis","volume":"24","author":"Dai","year":"2026","journal-title":"J. Nanobiotechnology"},{"issue":"24","key":"10.1016\/j.phrs.2026.108471_bib162","doi-asserted-by":"crossref","first-page":"6775","DOI":"10.1039\/D5BM00712G","article-title":"Tricobalt tetraselenide nanoparticles improve intestinal barrier function by reshaping the gut microbiota and fortifying epithelial tight junctions","volume":"13","author":"Chen","year":"2025","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.phrs.2026.108471_bib163","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001539","article-title":"Bile acid signaling in MASLD: From pathogenesis to therapeutic applications","author":"Simbrunner","year":"2025","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.phrs.2026.108471_bib164","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s12664-021-01220-5","article-title":"Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis","volume":"41","author":"Namisaki","year":"2022","journal-title":"Indian. J. Gastroenterol."},{"key":"10.1016\/j.phrs.2026.108471_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.fbio.2025.107727","article-title":"Propionylated high-amylose maize starch protects gut barrier function via GPR41\/43-IL-22-STAT3 signaling to alleviate alcoholic liver disease","volume":"73","author":"Liu","year":"2025","journal-title":"Food Biosci."},{"issue":"11","key":"10.1016\/j.phrs.2026.108471_bib166","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/s41423-025-01339-x","article-title":"Gut-derived indole propionic acid alleviates liver fibrosis by targeting profibrogenic macrophages via the gut-liver axis","volume":"22","author":"Luo","year":"2025","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib167","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s40168-021-01125-7","article-title":"Commensal microbe-derived acetate suppresses NAFLD\/NASH development via hepatic FFAR2 signalling in mice","volume":"9","author":"Aoki","year":"2021","journal-title":"Microbiome"},{"issue":"29","key":"10.1016\/j.phrs.2026.108471_bib168","doi-asserted-by":"crossref","first-page":"7633","DOI":"10.1021\/acs.jafc.8b01189","article-title":"Sodium Butyrate Ameliorates High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease through Peroxisome Proliferator-Activated Receptor \u03b1-Mediated Activation of \u03b2 Oxidation and Suppression of Inflammation","volume":"66","author":"Sun","year":"2018","journal-title":"J. Agric. Food Chem."},{"issue":"12","key":"10.1016\/j.phrs.2026.108471_bib169","doi-asserted-by":"crossref","first-page":"10675","DOI":"10.1039\/D0FO01954B","article-title":"Amelioration of non-alcoholic fatty liver disease by sodium butyrate is linked to the modulation of intestinal tight junctions in db\/db mice","volume":"11","author":"Yang","year":"2020","journal-title":"Food Funct."},{"key":"10.1016\/j.phrs.2026.108471_bib170","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122047","article-title":"Self-assembling polymer-based short chain fatty acid prodrugs ameliorate non-alcoholic steatohepatitis and liver fibrosis","volume":"295","author":"Shashni","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.phrs.2026.108471_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116519","article-title":"The effects of Atractylodes macrocephala extract BZEP self-microemulsion based on gut-liver axis HDL\/LPS signaling pathway to ameliorate metabolic dysfunction-associated fatty liver disease in rats","volume":"175","author":"Li","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.phrs.2026.108471_bib172","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s43587-025-00811-7","article-title":"A BCL-xL\/BCL-2 PROTAC effectively clears senescent cells in the liver and reduces MASH-driven hepatocellular carcinoma in mice","volume":"5","author":"Yang","year":"2025","journal-title":"Nat. Aging"},{"key":"10.1016\/j.phrs.2026.108471_bib173","article-title":"Reprogramming cellular senescence of hepatic stellate cells to combat liver fibrosis by targeted nanodrugs","volume":"33","author":"Fei","year":"2025","journal-title":"Mater. Today Bio"},{"issue":"4","key":"10.1016\/j.phrs.2026.108471_bib174","article-title":"CD36-PPAR\u03b3-SPP1 axis mediates hepatocyte-macrophage coordination to drive MASLD-related liver fibrosis","volume":"8","author":"Dai","year":"2026","journal-title":"JHEP Rep."},{"key":"10.1016\/j.phrs.2026.108471_bib175","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123694","article-title":"Chemotaxis-guided nanoplatform for non-alcoholic steatohepatitis therapy via macrophage reprogramming, hepatoprotection and gut microbiome modulation","volume":"326","author":"Pan","year":"2026","journal-title":"Biomaterials"},{"issue":"7","key":"10.1016\/j.phrs.2026.108471_bib176","article-title":"An Autologous Macrophage-Based Phenotypic Transformation-Collagen Degradation System Treating Advanced Liver Fibrosis","volume":"11","author":"Duan","year":"2024","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"8110","key":"10.1016\/j.phrs.2026.108471_bib177","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41586-026-10160-z","article-title":"RYK is a GPNMB receptor that drives MASH","volume":"652","author":"Xi","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2026.108471_bib178","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.mce.2019.02.005","article-title":"Relaxin and fibrosis: Emerging targets, challenges, and future directions","volume":"487","author":"Kanai","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108471_bib179","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41565-020-00836-6","article-title":"Hepatic macrophages act as a central hub for relaxin-mediated alleviation of liver fibrosis","volume":"16","author":"Hu","year":"2021","journal-title":"Nat. Nanotechnol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib180","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102807","article-title":"Circular RNA encoding relaxin-2 as a potential therapy for liver fibrosis","volume":"37","author":"Zhong","year":"2026","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.phrs.2026.108471_bib181","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116401","article-title":"Engineering a long acting, non-biased relaxin agonist using Protein-in-Protein technology","volume":"227","author":"Agoulnik","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108471_bib182","article-title":"PCK1 deficiency promotes MASH-HCC progression by 12-HETE-induced CD8(+) T cell dysfunction","author":"Wu","year":"2025","journal-title":"Gut"},{"issue":"13","key":"10.1016\/j.phrs.2026.108471_bib183","doi-asserted-by":"crossref","first-page":"5666","DOI":"10.7150\/ijbs.117394","article-title":"Immunotherapy resistance in MASLD-related hepatocellular carcinoma: special immune microenvironment and gut microbiota","volume":"21","author":"Jin","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.phrs.2026.108471_bib184","doi-asserted-by":"crossref","DOI":"10.1016\/j.arabjc.2023.104800","article-title":"Biosynthesized gold nanoparticles using leaf extract of Citrus medica inhibit hepatocellular carcinoma through regulation of the Wnt\/\u03b2-catenin signaling pathway","volume":"16","author":"Liu","year":"2023","journal-title":"Arab. J. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib185","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-026-04812-0","article-title":"Targeting STE20-type kinase MST3 improves metabolic dysfunction-associated steatohepatitis without affecting hepatocellular carcinoma development in mice","volume":"24","author":"Zhang","year":"2026","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib186","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-14435-9","article-title":"Role of CD133 antibody-conjugated nanocarrier in enhancing the targetability of hepatocellular carcinoma stem cells","volume":"15","author":"Aglan","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2026.108471_bib187","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2024.154173","article-title":"Development and efficacy evaluation of nanoliposomes targeting CAFs-LCSCs communication for hepatocellular carcinoma treatment","volume":"496","author":"Kong","year":"2024","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.phrs.2026.108471_bib188","author":"Orabi","year":"2025","journal-title":"Lipid Hydrolase ABHD6 Is. a Ther. Target. Metab. Dysfunct. -Assoc. Steatotic Liver Dis. (MASLD)-Relat. Hepatocell. Carcinoma bioRxiv"},{"key":"10.1016\/j.phrs.2026.108471_bib189","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.156192","article-title":"Multiscale identification of DNASE1L3 as a key target in MASLD progression to hepatocellular carcinoma","volume":"275","author":"Xia","year":"2025","journal-title":"Pathol. Res. Pract."},{"issue":"17","key":"10.1016\/j.phrs.2026.108471_bib190","doi-asserted-by":"crossref","first-page":"6798","DOI":"10.7150\/thno.102995","article-title":"DNASE1L3-mediated PANoptosis enhances the efficacy of combination therapy for advanced hepatocellular carcinoma","volume":"14","author":"Wang","year":"2024","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.phrs.2026.108471_bib191","doi-asserted-by":"crossref","first-page":"587","DOI":"10.14740\/wjon2646","article-title":"A Tertiary Lymphoid Structure-Related Gene Signature Predicts Prognosis and Treatment Response in Hepatocellular Carcinoma","volume":"16","author":"Kong","year":"2025","journal-title":"World J. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib192","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.tem.2025.04.009","article-title":"TREM2-expressing macrophages in liver diseases","volume":"37","author":"Wang","year":"2026","journal-title":"Trends Endocrinol. Metab."},{"issue":"22","key":"10.1016\/j.phrs.2026.108471_bib193","doi-asserted-by":"crossref","first-page":"6743","DOI":"10.1021\/acs.nanolett.4c01458","article-title":"Helper Lipid-Enhanced mRNA Delivery for Treating Metabolic Dysfunction-Associated Fatty Liver Disease","volume":"24","author":"Guo","year":"2024","journal-title":"Nano Lett."},{"issue":"12","key":"10.1016\/j.phrs.2026.108471_bib194","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.31557\/APJCP.2022.23.12.4261","article-title":"Nanotherapy: New Approach for Impeding Hepatic Cancer Microenvironment via Targeting Multiple Molecular Pathways","volume":"23","author":"Abd-Rabou","year":"2022","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"7","key":"10.1016\/j.phrs.2026.108471_bib195","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.31557\/APJCP.2019.20.7.2225","article-title":"Bevacizumab and CCR2 Inhibitor Nanoparticles Induce Cytotoxicity-Mediated Apoptosis in Doxorubicin-Treated Hepatic and Non-Small Lung Cancer Cells","volume":"20","author":"Abd-Rabou","year":"2019","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"24","key":"10.1016\/j.phrs.2026.108471_bib196","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa2502242","article-title":"Efruxifermin in Compensated Liver Cirrhosis Caused by MASH","volume":"392","author":"Noureddin","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2026.108471_bib197","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123321","article-title":"Engineered extracellular vesicles with surface FGF21 and enclosed miR-223 for treating metabolic dysfunction-associated steatohepatitis","volume":"321","author":"Cho","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.phrs.2026.108471_bib198","article-title":"Self-assembled FGF21 nanoparticles alleviate drug-induced acute liver injury","volume":"13","author":"Huang","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib199","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12943-025-02370-2","article-title":"Single-cell transcriptome reveals the reprogramming of immune microenvironment during the transition from MASH to HCC","volume":"24","author":"Huang","year":"2025","journal-title":"Mol. Cancer"},{"issue":"827","key":"10.1016\/j.phrs.2026.108471_bib200","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adv2293","article-title":"Metabolism-programming mRNA-lipid nanoparticles remodel the immune microenvironment to improve immunotherapy against MAFLD","volume":"17","author":"Yu","year":"2025","journal-title":"Sci. Transl. Med."},{"issue":"23","key":"10.1016\/j.phrs.2026.108471_bib201","doi-asserted-by":"crossref","DOI":"10.1172\/JCI175305","article-title":"The Nr4a family regulates intrahepatic Treg proliferation and liver fibrosis in MASLD models","volume":"134","author":"Aki","year":"2024","journal-title":"J. Clin. Invest."},{"issue":"17","key":"10.1016\/j.phrs.2026.108471_bib202","doi-asserted-by":"crossref","first-page":"24193","DOI":"10.1021\/acsami.6c02880","article-title":"Genetically Engineered Membrane-Mimetic Liposome-Wrapped Violet Phosphorus Nanoplatform for Targeted Synergistic Ferroptosis\/Photothermal\/Immunotherapy of Hepatocellular Carcinoma","volume":"18","author":"Li","year":"2026","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib203","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-65056-9","article-title":"Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma","volume":"16","author":"Tang","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib204","article-title":"Biomimetic \u03b2-lapachone and hemin nanoassembly for intracellular oxidation cascade amplified ferroptosis in hepatocellular carcinoma therapy","volume":"24","author":"Wang","year":"2026","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.phrs.2026.108471_bib205","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2026.174817","article-title":"A stimuli-responsive polymeric ferroptosis drug delivery system for treatment of liver metastases","volume":"533","author":"Deng","year":"2026","journal-title":"Chem. Eng. J."},{"issue":"8","key":"10.1016\/j.phrs.2026.108471_bib206","article-title":"A Dual-Targeting Biomimetic Nanoplatform Integrates SDT\/CDT\/Gas Therapy to Boost Synergistic Ferroptosis for Orthotopic Hepatocellular Carcinoma Therapy","volume":"12","author":"Meng","year":"2025","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"2","key":"10.1016\/j.phrs.2026.108471_bib207","doi-asserted-by":"crossref","first-page":"465","DOI":"10.4103\/jcrt.jcrt_1531_24","article-title":"MSNs-loaded HMME and Erastin-mediated ferroptosis combined with sonodynamic therapy for HCC treatment","volume":"21","author":"Zhao","year":"2025","journal-title":"J. Cancer Res. Ther."},{"key":"10.1016\/j.phrs.2026.108471_bib208","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfa.2025.137049","article-title":"Dual inhibition of GPX4 and LCN2 via miR-214-3p loaded iron oxide nanoparticles for enhancing ferroptosis in liver cancer","volume":"719","author":"An","year":"2025","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"issue":"32","key":"10.1016\/j.phrs.2026.108471_bib209","article-title":"Copper-Based Nanotubes That Enhance Starvation Therapy Through Cuproptosis for Synergistic Cancer Treatment","volume":"12","author":"Han","year":"2025","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"29","key":"10.1016\/j.phrs.2026.108471_bib210","article-title":"Responsive ROS-Augmented Prodrug Hybridization Nanoassemblies for Multidimensionally Synergitic Treatment of Hepatocellular Carcinoma in Cascade Assaults","volume":"12","author":"Zeng","year":"2025","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib211","doi-asserted-by":"crossref","DOI":"10.1007\/s10856-026-07045-y","article-title":"Bioinspired polymer-incorporated copper\/iron nanozyme to boost cascade ROS accumulation for augmented hepatocellular carcinoma cuproptosis\/ferroptosis","volume":"37","author":"Zhang","year":"2026","journal-title":"J. Mater. Sci. Mater. Med."},{"issue":"6","key":"10.1016\/j.phrs.2026.108471_bib212","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202503530","article-title":"A Functional Nanocomposite Tri-Activates Cuproptosis, Ferroptosis, and Mitophagy Death Pathway to Oppose Malignancies","volume":"15","author":"Deng","year":"2026","journal-title":"Adv. Healthc. Mater."},{"issue":"43","key":"10.1016\/j.phrs.2026.108471_bib213","doi-asserted-by":"crossref","first-page":"58203","DOI":"10.1021\/acsami.4c10336","article-title":"\"Trinity\" Comprehensively Regulates the Tumor Microenvironment of Lipid-Coated CaCO(3)@CuO(2) Nanoparticles Induces \"Cuproptosis\" in HCC","volume":"16","author":"Li","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"37","key":"10.1016\/j.phrs.2026.108471_bib214","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202501259","article-title":"Oligocopper-Loaded Lipoic Acid Nanoparticles Promote Mitochondrial Protein Lipoylation for Augmented Cuproptosis Therapy","volume":"21","author":"Chen","year":"2025","journal-title":"Small"},{"key":"10.1016\/j.phrs.2026.108471_bib215","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.bios.2019.04.045","article-title":"Porous graphene-black phosphorus nanocomposite modified electrode for detection of leptin","volume":"137","author":"Cai","year":"2019","journal-title":"Biosens. Bioelectron."},{"key":"10.1016\/j.phrs.2026.108471_bib216","article-title":"A multiplexed laser-scribed graphene immunosensor for simultaneous detection of adiponectin and leptin: A point-of-care solution for early insulin resistance diagnosis","volume":"9","author":"Rizalputri","year":"2025","journal-title":"Sens. Actuators Rep."},{"issue":"4","key":"10.1016\/j.phrs.2026.108471_bib217","doi-asserted-by":"crossref","first-page":"5647","DOI":"10.1021\/acsnano.1c10618","article-title":"Heterogeneous Iron Oxide\/Dysprosium Oxide Nanoparticles Target Liver for Precise Magnetic Resonance Imaging of Liver Fibrosis","volume":"16","author":"Balachandran","year":"2022","journal-title":"ACS Nano"},{"issue":"11","key":"10.1016\/j.phrs.2026.108471_bib218","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/s41587-023-01680-4","article-title":"Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis","volume":"41","author":"Hendriks","year":"2023","journal-title":"Nat. Biotechnol."},{"issue":"10","key":"10.1016\/j.phrs.2026.108471_bib219","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S2468-1253(25)00128-1","article-title":"Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study","volume":"10","author":"Wong","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108471_bib220","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000949","article-title":"GLP-1RA plus SGLT2i combination therapy and liver fibrosis progression in MASLD with type 2 diabetes","volume":"10","author":"Choi","year":"2026","journal-title":"Hepatol. Commun."},{"issue":"11","key":"10.1016\/j.phrs.2026.108471_bib221","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.cmet.2025.09.011","article-title":"The enedioic acid analog 326E alleviates metabolic dysfunction-associated steatohepatitis via dual targeting at ACLY and PPAR\u03b1","volume":"37","author":"Xie","year":"2025","journal-title":"Cell. Metab."},{"issue":"5","key":"10.1016\/j.phrs.2026.108471_bib222","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.cmet.2025.01.016","article-title":"Hepatic sphingomyelin phosphodiesterase 3 promotes steatohepatitis by disrupting membrane sphingolipid metabolism","volume":"37","author":"Jiang","year":"2025","journal-title":"Cell. Metab."},{"issue":"4","key":"10.1016\/j.phrs.2026.108471_bib223","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines14040909","article-title":"Current Drug Development Pipeline for MASLD and MASH: Focusing on Cardiovascular Comorbidities","volume":"14","author":"Prikhodko","year":"2026","journal-title":"Biomedicines"},{"key":"10.1016\/j.phrs.2026.108471_bib224","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.actbio.2025.07.010","article-title":"A ROS\/ultrasound dual-responsive nanocarrier enhances drug penetration for ameliorating metabolic dysfunction-associated steatohepatitis","volume":"202","author":"Liang","year":"2025","journal-title":"Acta Biomater."},{"issue":"13","key":"10.1016\/j.phrs.2026.108471_bib225","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1039\/D5TB02289D","article-title":"Galactose-decorated lipid nanoparticle-mediated delivery of a selective NLRP3 inhibitor attenuates hepatic inflammation in metabolic dysfunction-associated steatotic liver disease","volume":"14","author":"Niu","year":"2026","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.phrs.2026.108471_bib226","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2025.123723","article-title":"Comprehensive study of the murine MASH models' applicability by comparing human liver transcriptomes","volume":"376","author":"Ning","year":"2025","journal-title":"Life Sci."},{"issue":"12","key":"10.1016\/j.phrs.2026.108471_bib227","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1080\/17460441.2025.2579124","article-title":"Animal models of lean metabolic dysfunction-associated steatotic liver disease (MASLD): bridging pathogenesis and novel drug discovery","volume":"20","author":"Papadakos","year":"2025","journal-title":"Expert. Opin. Drug. Discov."},{"issue":"6","key":"10.1016\/j.phrs.2026.108471_bib228","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s42255-024-01043-6","article-title":"L.I. The, An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"6","author":"Vacca","year":"2024","journal-title":"Nat. Metab."},{"issue":"11","key":"10.1016\/j.phrs.2026.108471_bib229","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/s41587-023-01680-4","article-title":"Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis","volume":"41","author":"Hendriks","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.phrs.2026.108471_bib230","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2023.103045","article-title":"Progress and challenges in the translation of cancer nanomedicines","volume":"85","author":"Tong","year":"2024","journal-title":"Curr. Opin. Biotechnol."},{"issue":"12","key":"10.1016\/j.phrs.2026.108471_bib231","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1016\/j.xphs.2024.09.015","article-title":"S.M. D\u2032Addio, Review of machine learning for lipid nanoparticle formulation and process development","volume":"113","author":"Dorsey","year":"2024","journal-title":"J. Pharm. Sci."},{"issue":"10","key":"10.1016\/j.phrs.2026.108471_bib232","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/s41565-025-01975-4","article-title":"Designing lipid nanoparticles using a transformer-based neural network","volume":"20","author":"Chan","year":"2025","journal-title":"Nat. Nanotechnol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108471_bib233","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1038\/s41467-025-59885-x","article-title":"Nucleic acid spheres for treating capillarisation of liver sinusoidal endothelial cells in liver fibrosis","volume":"16","author":"Liu","year":"2025","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.phrs.2026.108471_bib234","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.tips.2024.05.004","article-title":"Implications of innate immune sexual dimorphism for MASLD pathogenesis and treatment","volume":"45","author":"Booijink","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.phrs.2026.108471_bib235","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16088","article-title":"Sex-specific effects of PNPLA3 I148M","volume":"45","author":"Cherubini","year":"2025","journal-title":"Liver Int."},{"issue":"2","key":"10.1016\/j.phrs.2026.108471_bib236","article-title":"Advances in nanotechnology for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease","volume":"20","author":"Li","year":"2025","journal-title":"Asian J. Pharm. Sci."},{"issue":"Pt 1","key":"10.1016\/j.phrs.2026.108471_bib237","article-title":"A multifunctional L-arginine-linked melanin Nanozyme for Theranostic applications in liver fibrosis: Non-invasive dual-modal imaging and reactive oxygen species scavenging for Pyroptosis suppression","volume":"702","author":"Li","year":"2026","journal-title":"J. Colloid Interface Sci."},{"issue":"45","key":"10.1016\/j.phrs.2026.108471_bib238","article-title":"Oral celastrol micelles forming high-density lipoprotein corona targeting hepatocytes for MASLD treatment","volume":"12","author":"Xu","year":"2025","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"9","key":"10.1016\/j.phrs.2026.108471_bib239","article-title":"Oral administration of DSPE-PEG-cholic acid-modified ACDVs loaded with siLIMA1 for anti-MASH therapy","volume":"1","author":"Yang","year":"2025","journal-title":"Cell. Biomater."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826003865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826003865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:40:20Z","timestamp":1793263220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826003865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":239,"alternative-id":["S1043661826003865"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108471","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanomedicine-based targeted strategies for metabolic dysfunction-associated steatotic liver disease: Unraveling pathogenic crosstalk and overcoming clinical barriers","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108471","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108471"}}